A peripheral blood DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease

Jiantao Ma, Jana Nano, Jingzhong Ding, Yinan Zheng, Rachel Hennein, Chunyu Liu, Elizabeth K. Speliotes, Tianxiao Huan, Ci Song, Michael M. Mendelson, Roby Joehanes, Michelle T. Long, Liming Liang, Jennifer A. Smith, Lindsay M. Reynolds, Mohsen Ghanbari, Taulant Muka, Joyce B.J. Van Meurs, Louise J.M. Alferink, Oscar H. FrancoAbbas Dehghan, Scott Ratliff, Wei Zhao, Lawrence Bielak, Sharon L.R. Kardia, Patricia A. Peyser, Hongyan Ning, Lisa B. VanWagner, Donald M. Lloyd-Jones, John Jeffrey Carr, Philip Greenland, Alice H. Lichtenstein, Frank B. Hu, Yongmei Liu, Lifang Hou, Sarwa Darwish Murad, Daniel Levy*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

47 Scopus citations

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a risk factor for type 2 diabetes (T2D). We aimed to identify the peripheral blood DNA methylation signature of hepatic fat. We conducted epigenome-wide association studies of hepatic fat in 3,400 European ancestry (EA) participants and in 401 Hispanic ancestry and 724 African ancestry participants from four population-based cohort studies. Hepatic fat was measured using computed tomography or ultrasound imaging and DNA methylation was assessed at >400,000 cytosine-guanine dinucleotides (CpGs) in whole blood or CD14+ monocytes using a commercial array. We identified 22 CpGs associated with hepatic fat in EA participants at a false discovery rate <0.05 (corresponding P = 6.9 × 10-6) with replication at Bonferroni-corrected P < 8.6 × 10-4. Mendelian randomization analyses supported the association of hypomethylation of cg08309687 (LINC00649) with NAFLD (P = 2.5 × 10-4). Hypomethylation of the same CpG was also associated with risk for new-onset T2D (P = 0.005). Our study demonstrates that a peripheral blood-derived DNA methylation signature is robustly associated with hepatic fat accumulation. The hepatic fat-associated CpGs may represent attractive biomarkers for T2D. Future studies are warranted to explore mechanisms and to examine DNAmethylation signatures of NAFLD across racial/ethnic groups.

Original languageEnglish (US)
Pages (from-to)1073-1083
Number of pages11
JournalDiabetes
Volume68
Issue number5
DOIs
StatePublished - 2019

Funding

Infrastructure for the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium is supported in part by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grant R01- HL-105756. This work was supported in part by the Intramural Research Program of the NIH: NHLBI; National Institute on Aging (NIA); and National Institute of Environmental Health Sciences. The FHS is funded by NIH contract N01- HC-25195. The laboratory work for this investigation was funded by the Division of Intramural Research, NHLBI, NIH, Bethesda, MD. The analytical component of this project was funded by the Division of Intramural Research, NHLBI, and the Center for Information Technology, NIH. The generation and management of the Illumina HumanMethylation450K BeadChip array data (EWAS data) for the RS was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus University Medical Center. The EWAS data were funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus University Medical Center, and by the Netherlands Organization for Scientific Research (NWO) (project number 184021007) and made available as a Rainbow Project (RP3 [Biobank-based Integrative Omics Study (BIOS)]) of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL). The RS is funded by Erasmus University Medical Center and Erasmus University, Rotterdam; Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (Directorate-General XII); and the Municipality of Rotterdam. MESA and the MESA SHARe (SNP Health Association Resource) project are conducted and supported by the NHLBI in collaboration with MESA investigators. Support for MESA is provided by contracts NIH N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC- 95169, UL1-TR-001079, UL1-TR-000040, and DK063491. The MESA Epigenomics and Transcriptomics Study was funded by NIA grant 1R01HL101250-01 to Wake Forest University Health Sciences. CARDIA is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C and grant R01-HL098445 for the year 25 CT exam (J.J.C.) from the NHLBI. The laboratory work and analytical component were funded by the American Heart Association (17SFRN33700278 and 14SFRN20790000 [L.H.]). L.B.V. is supported by NHLBI grant K23-HL-136891. Support for GENOA was provided by the NHLBI of the NIH (HL-054464, HL-054457, HL-054481, HL-100185, HL-119443, HL-085571, and HL-133221). Acknowledgments. The authors thank Michael Verbiest, Mila Jhamai, Sarah Higgins, Marijn Verkerk, and Lisette Stolk (Erasmus Medical Center and Erasmus University, Rotterdam, the Netherlands) for their help in creating the methylation database. The authors are grateful to the study participants, the staff from the RS, and the participating general practitioners and pharmacists. The authors also thank the families that participated in GENOA. Funding. Infrastructure for the CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology) Consortium is supported in part by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grant R01-HL-105756. This work was supported in part by the Intramural Research Program of the NIH: NHLBI; National Institute on Aging (NIA); and National Institute of Environmental Health Sciences. The FHS is funded by NIH contract N01-HC-25195. The laboratory work for this investigation was funded by the Division of Intramural Research, NHLBI, NIH, Bethesda, MD. The analytical component of this project was funded by the Division of Intramural Research, NHLBI, and the Center for Information Technology, NIH. The generation and management of the Illumina HumanMethylation450K BeadChip array data (EWAS data) for the RS was executed by the Human Genotyping Facility of the Genetic Laboratory of the Department of Internal Medicine, Erasmus University Medical Center. The EWAS data were funded by the Genetic Laboratory of the Department of Internal Medicine, Erasmus University Medical Center, and by the Netherlands Organization for Scientific Research (NWO) (project number 184021007) and made available as a Rainbow Project (RP3 [Biobank-based Integrative Omics Study (BIOS)]) of the Biobanking and Biomolecular Research Infrastructure Netherlands (BBMRI-NL). The RS is funded by Erasmus University Medical Center and Erasmus University, Rotterdam; Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the European Commission (Directorate-General XII); and the Municipality of Rotterdam. MESA and the MESA SHARe (SNP Health Association Resource) project are conducted and supported by the NHLBI in collaboration with MESA investigators. Support for MESA is provided by contracts NIH N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-001079, UL1-TR-000040, and DK063491. The MESA Epigenom-ics and Transcriptomics Study was funded by NIA grant 1R01HL101250-01 to Wake Forest University Health Sciences. CARDIA is supported by contracts HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, and HHSN268200900041C and grant R01-HL098445 for the year 25 CT exam (J.J.C.) from the NHLBI. The laboratory work and analytical component were funded by the American Heart Association (17SFRN33700278 and 14SFRN20790000 [L.H.]). L.B.V. is supported by NHLBI grant K23-HL-136891. Support for GENOA was provided by the NHLBI of the NIH (HL-054464, HL-054457, HL-054481, HL-100185, HL-119443, HL-085571, and HL-133221).

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Fingerprint

Dive into the research topics of 'A peripheral blood DNA methylation signature of hepatic fat reveals a potential causal pathway for nonalcoholic fatty liver disease'. Together they form a unique fingerprint.

Cite this